Compare PubMatic Inc (PUBM) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? PubMatic Inc trades at $18.63 (market cap $850.88M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.75 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 69× PubMatic Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| PUBM | TAK | |
|---|---|---|
Market Cap | $850.88M | $58.74B |
Volume | 997,698 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $19.18 | $19.05 |
52-Week Low | $6.28 | $13.23 |
Typical Hold Time | 40 Days | 1 Days |
Enterprise Value | $754.01M | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $18.72, up 0.81% with bullish technical signals from moving averages. The company shows mixed fundamentals with strong revenue growth but negative profitability metrics, including a -4.66% net margin. Recent Q2 2026 earnings beat expectations with -$0.03 EPS versus -$0.18 expected, while analyst consensus remains strongly positive with 11 buy ratings and a $19.89 price target. Operating cash flow improved to $81M in 2025, supporting business stability.
The outlook suggests potential upside near analyst targets, though profitability challenges and CFO transition pose risks. Revenue growth in mobile app and CTV segments provides catalysts, while high P/E of 132 indicates premium valuation. Investment opportunity exists for growth-focused investors tolerant of current losses, with sentiment supported by AI-driven ad tech adoption.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
